Circulatory System
Conditions
Interventions
placebo via Nasogastric tube or oral route
Enteral Midodrine 10mg
Enteral Midodrine 20mg
Sponsors
Menofia university hospitals
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Adults =18 years and = 65 years. • Patients have Septic Shock with Stable or decreasing vasopressor requirements (e.g., norepinephrine 0.1–0.3 mcg/kg/min). • Evidence of perfusion: Improving lactate, adequate urine output (>0.5 mL/kg/hr), warm extremities. • Functional Gastrointestinal Tract (absence of ileus, severe abdominal distension, or high gastric residuals)
Exclusion criteria
Exclusion criteria: • Known hypersensitivity to midodrine. • Active myocardial ischemia or severe cardiac dysfunction (EF< 40%). • End-stage renal disease on dialysis. • Expected death within 24 hours (e.g. patients in irreversible shock despite maximum dose of vasopressors). • Contraindication to enteral drug administration. • Pregnancy or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The time required to successfully wean intravenous vasopressors. Successful weaning is defined as discontinuing all vasopressor infusions for at least 24 consecutive hours without needing to restart them. | — |
Secondary
| Measure | Time frame |
|---|---|
| ICU length of stay.;Adverse events (hypertension, ischemia, bradycardia, Hypersensitivity reaction).;ICU mortality at 28 days. | — |
Countries
Egypt
Contacts
Public ContactElsayed Bedir
ICU resident
Outcome results
None listed